Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiac Safety and Trauma Trial Design Subject Of Hemopure Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Blood Products Advisory Committee review could give the agency the green light to lift the clinical hold on the hemoglobin-based oxygen therapeutic.

You may also be interested in...



U.S. Navy Plans To Proceed With Hemopure Development

Following negative review by FDA advisory committee, Navy will work on a revised clinical trial protocol for a scaled-down Phase II study.

U.S. Navy Plans To Proceed With Hemopure Development

Following negative review by FDA advisory committee, Navy will work on a revised clinical trial protocol for a scaled-down Phase II study.

Sen. Grassley Presses HHS On Ethics Of FDA-Approved Blood Substitute Study

Grassley wants an investigation into FDA’s approval of a protocol that allowed patients to be treated with a blood substitute even though blood was available.

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel